Examination of Inter‐α Inhibitor Proteins in Permanent and Transient Focal Ischemia

 Will your competent? doctor ENSURE HUMAN TESTING GETS DONE? NO? So, you DON'T have a functioning stroke doctor, do you?

Examination of Inter‐α Inhibitor Proteins in Permanent and Transient Focal Ischemia

Takahiko Imai, PhD https://orcid.org/0000-0002-4422-2946, Andreia Lopes de Morais, PhD https://orcid.org/0000-0002-9351-2552, Tao Qin, BS, Yuichi Sasaki, MD, PhD, Yow‐Pin Lim, MD, PhD https://orcid.org/0000-0003-2697-7963, and Cenk Ayata, MD, PhD https://orcid.org/0000-0002-3644-6042 cayata@mgh.harvard.eduAuthor Info & Affiliations

Journal of the American Heart Association

New online

https://doi.org/10.1161/JAHA.124.036034

• Abstract
• Nonstandard Abbreviations and Acronyms
• Research Perspective
• METHODS
• RESULTS
• DISCUSSION
• Source of Funding
• Acknowledgments
• Footnotes
• Supplemental Material
• References
• eLetters

• Information & Authors
• Metrics & Citations
• View Options
• References
• Figures
• Tables

• • Share

Abstract

Background

Ischemic stroke is among the most prevalent diseases, with high death and morbidity. Numerous preclinical studies have reported efficacious interventions in rodent stroke models. However, reperfusion therapies remain the only clinically efficacious intervention to date. Rigor and reproducibility are now recognized as critical to bridge the preclinical–clinical disconnect. Inter‐α inhibitor proteins (IαIPs) are a family of structurally related glycoproteins with 2 major forms (inter‐α inhibitor and pre‐α inhibitor) in blood. Purified human plasma–derived IαIP has beneficial effects in sepsis and hypoxic–ischemic brain injury. More recently, IαIP improved focal ischemic stroke outcomes in mouse models. Here, we tested IαIP efficacy in both transient and permanent stroke mouse models, mimicking previously published study designs and protocols to seek reproducibility.

Methods and Results

Using healthy young male and female C57BL/6 mice, we induced transient or permanent endovascular filament middle cerebral artery occlusion (MCAO). Mice were divided into transient MCAO+vehicle, transient MCAO+IαIP (30 mg/kg), permanent MCAO+vehicle, and permanent MCAO+IαIP groups. IαIP or vehicle was administered intravenously at 6 and 18 hours after MCAO. End points were assessed at 2 days. Efficacy readouts included death, infarct volume and swelling, and 3 neurological tests. Contrary to the previous work, we did not find IαIP efficacious on any outcome readout in either transient MCAO or permanent MCAO.

Conclusions

Our data highlight the contribution of interlaboratory heterogeneity to study outcomes and suggest that interventions considered for clinical development should undergo rigorous testing in multiple single‐laboratory studies before entering a multicenter preclinical trial.